Evolus delivered Q2 2026 revenue growth of 21% and posted positive adjusted EBITDA for the third consecutive quarter, a milestone that signals the company has moved past the cash-burn phase and into sustainable profitability. The earnings beat also prompted management to raise full-year 2026 guidance, a rare move that reflects confidence in Jeuveau's market penetration and the company's ability to manage unit economics.
Business & M&A
Evolus Posts Third Straight Profitable Quarter
Q2 revenue up 21%; adjusted EBITDA positive for third consecutive quarter; 2026 outlook raised.

1-YEAR MOVE
EOLS
▼15.6%
ABBV
▲11.6%
| Ticker | Company | 1-year change |
|---|---|---|
| EOLS | Evolus | −15.6% |
| ABBV | AbbVie (Allergan Aesthetics) | +11.6% |